

Section S: Blood Product Overview -

Voluven® 6% HydroxyEthylStarch (HEX) in 0.9% NaCl *Fresenius Kabi Canada*

Page
1 of 5

DESCRIPTION of PRODUCT	1
AVAILABILITY of PRODUCT	1
STORAGE of PRODUCT	1
CLINICAL INDICATIONS (see package insert for additional contraindications)	2
CONTRAINDICATIONS	2
REQUESTS for VOLUVEN	2
ADMINISTRATION of PRODUCT	2
ADDITIONAL COMMENTS	3
LINK to WEBSITE for PRESCRIBING INFORMATION	3
APPENDIX: <i>Excerpt from Practical Guide to Infusion with Voluven®</i>	4

DESCRIPTION of PRODUCT

- **Voluven is NOT a blood product.**
- 6% Hydroxy Ethyl Starch (130/0.4) in 0.9% Sodium Chloride.
- Supplied in freeflex® packaging which features PVC and latex free flexible infusion bag.
- Demonstrated effective plasma volume expansion for 4 to 6 hours.

AVAILABILITY of PRODUCT

- 250mL and 500mL size Voluven is stocked in all LHSC/SJHC Blood Transfusion Laboratories
- It is also issued for stock, to certain patient care areas that have high and/or urgent need for Voluven.

STORAGE of PRODUCT

- Store at Room Temperature (15 - 25°C).
- Avoid excessive heat and freezing.

Date effective: Mar 2008

Date revised: Dec 2009

Section S: Blood Product Overview -

Voluven® 6% HydroxyEthylStarch (HEX) in 0.9% NaCl *Fresenius Kabi Canada*

Page
2 of 5

CLINICAL INDICATIONS (see package insert for additional contraindications)

- Treatment of hypovolemia when plasma volume expansion is required.
- Does **not** contain IgA: recommended product for volume replacement in patients with anti-IgA.

CONTRAINDICATIONS

- Patients with fluid overload or cases of pulmonary edema and congestive cardiac failure.
- Known hypersensitivity to hydroxyethyl starch.
- Renal failure with oliguria or anuria not related to hypovolemia.
- Patients with severe hypernatremia or severe hyperchloremia.
- Patients with intracranial bleeding.

REQUESTS for VOLUVEN

- Issued as requested. No BTL specimen required.
- Product will be issued 'patient specific' for areas that do not stock Voluven.
- Product will be issued for stock, in the areas that have been approved for stocking Voluven,

ADMINISTRATION of PRODUCT

- Do NOT administer product if on visual inspection:
 - the product is past the expiry date
 - the product looks turbid, has a dark color, or there is a formation of a crystalline precipitate in the product.
- Administer by intravenous infusion only. Blood Transfusion Set with 170-240µ filter is NOT required.
- Compatible with 0.9% sodium chloride. Mixing with other drugs should be avoided.
- Rate of infusion is dependant on clinical situation and should be specified by ordering physician; however, the initial 10-20mL should be infused slowly, keeping the patient under close observation due to possible anaphylactoid reactions.
- Total volume is dependant on clinical situation. In clinical trials, infusions up to 33mL / kg / day were most commonly used.
- The *Practical Guide to Infusion with Voluven*® (see [excerpt, Appendix A](#)) provides step-by-step instructions for removing outer wrap, accessing BLUE infusion port, and spiking product.

Date effective: Mar 2008

Date revised: Dec 2009

Section S: Blood Product Overview -

Voluven® 6% HydroxyEthylStarch (HEX) in 0.9% NaCl

Fresenius Kabi Canada

Page

3 of 5

ADDITIONAL COMMENTS

- Voluven is not a blood product, but when issued for a specific patient, a label from the Blood Transfusion Lab will be sent. This label should be placed in the lab section of the patient's chart (see [Section H](#) Administration of Blood Products – XII: Documentation). Volume of Voluven administered should also be documented in the Fluid Balance sheets.
- If the product was not obtained from the Blood Transfusion Lab, the volume of Voluven should be noted in either the Fluid Balance sheets, or in the OR record.

LINK to WEBSITE for PRESCRIBING INFORMATION

Product monograph available at

<http://www.fresenius-kabi.ca/pdfs/Voluven%20Product%20Monograph%20Eng%20Oct07.pdf>

Date effective: Mar 2008

Date revised: Dec 2009

This is a controlled document. Any copies appearing in paper form must be checked against the electronic version prior to use.

This resource has been created specifically for LHSC/SJHC and may not be applicable for other centres.

These documents are the intellectual property of LHSC/SJHC. They are not to be shared or duplicated without permission

Section S: Blood Product Overview -

Volugen® 6% HydroxyEthylStarch (HEX) in 0.9% NaCl Fresenius Kabi Canada

APPENDIX: Excerpt from Practical Guide to Infusion with Volugen®


VOLUVEN®

Special Handling and Instructions

Before administering, review these directions:

These instructions are only intended as guidelines for product use. Please refer to your own departmental guidelines.


1. Preparation for administration




2. Check the freeflex® IV container solution composition, lot number and expiry date. Inspect the container for damage or solution leakage. If damaged, do not use! Check the freeflex® solution for visible particles or cloudiness. Do not use unless the solution is clear.



3. Turn the freeflex® IV container over so that the text is face down. Using the pre-cut corner tabs, peel open the overwrap to remove the primary bag. The overwrap adheres slightly to the primary bag to improve handling even when wearing disposable gloves.




4. Identify the blue infusion port. Check the freeflex® for visible particles or cloudiness. Do not administer unless the solution is clear.




Section S: Blood Product Overview -

Voluven® 6% HydroxyEthylStarch (HEX) in 0.9% NaCl Fresenius Kabi Canada

5. Flip off the blue tamper-evident cover from the freeflex® IV container infusion port.



6. Use a non-vented giving set or, if using a vented set, close the air inlet. Grip the base of the infusion port with your fingers behind the guard. Push and twist the giving set firmly into the port. A slight resistance should be felt, as the port membrane is broken. To prevent leaks, insert the spike until the clear plastic collar of the port meets the shoulder of the spike.



Caution

1. Do not remove the freeflex® IV container from its overwrap until immediately before use.
2. Do not administer unless the solution is clear, free from particles and the freeflex® IV container is undamaged.
3. Discontinue the infusion if adverse reaction occurs.
4. Do not vent.
5. It is recommended that administration sets are changed at least once every 24 hours.
6. Partially used freeflex® IV containers must be discarded.

Incompatibilities

Mixing with other drugs should be avoided. If, in exceptional cases, a mixture with other drugs is required, care should be taken with the compatibility (clouding or precipitation), hygienic injection and a good admixture.